Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527773 | 0.84 | LOXL2 (0.48) | LOXL2PNMTTAAR1 | |
| SCHEMBL28793914 | 0.82 | TAAR1 (0.48) | KDM1AKCNH2KDM1BTAAR1 | |
| SCHEMBL1363756 | 0.81 | TAAR1 (0.46) | KDM1AKCNH2KDM1BLOXL2PNMT | |
| SCHEMBL22659331 | 0.80 | KDM1A (0.32) | KDM1AKCNH2KDM1BLOXL2 | |
| SCHEMBL30758607 | 0.80 | KDM1A (0.38) | KDM1AKCNH2KDM1B | |
| SCHEMBL6121258 | 0.80 | KDM1A (0.38) | KDM1AKCNH2KDM1B | |
| Hydrochloric Acid SCHEMBL1363546 | 0.79 | TAAR1 (0.45) | KDM1AKCNH2KDM1BLOXL2PNMT | |
| Hydrochloric Acid SCHEMBL25230650 | 0.79 | KDM1A (0.32) | KDM1AKCNH2KDM1BLOXL2 | |
| SCHEMBL23336450 | 0.77 | KDM1A (0.31) | KDM1AKCNH2KDM1B | |
| SCHEMBL26048165 | 0.77 | KDM1A (0.31) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018075871-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | THE BROAD INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | KDM1A 4126/4885KCNH2 3749/4885KDM1B 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.